Results

Total Results: 8,575 records

Showing results for "infants".

  1. www.ahrq.gov/sites/default/files/wysiwyg/research/findings/nhqrdr/2019qdr-intro-methods-cx061721.pdf
    December 01, 2020 - National Tuberculosis Surveillance System (NTSS) • National Vital Statistics System—Linked Birth and Infant
  2. effectivehealthcare.ahrq.gov/health-topics/childhood-brain-tumors
  3. effectivehealthcare.ahrq.gov/health-topics/vitamin-d/
  4. www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/inline-files/uspstf-annual-report-to-congress-2019.pdf
    January 01, 2019 - funded by the Centers for Disease Control and Prevention, which aims to improve outcomes for women and infants … USPSTF recommends that primary care clinicians apply fluoride varnish to the primary teeth of all infants
  5. www.uspreventiveservicestaskforce.org/home/getfilebytoken/KYaqKCUyn2rjUGfoS977h8
    July 10, 2023 - In the trial of cisgender women, no congenital abnormalities were observed in infants of those who … for PrEP during pregnancy is very sparse, al- though 1 trial7 reported no congenital abnormalities in infants
  6. effectivehealthcare.ahrq.gov/sites/default/files/pdf/chronic-urinary-retention_research.pdf
    September 01, 2014 - Women and Infants’ Hospital of Rhode Island Providence, RI John Wei, M.D., M.S. … Women and Infants’ Hospital of Rhode Island Providence, RI John Wei, M.D., M.S.
  7. effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/chronic-urinary-retention_research.pdf
    September 01, 2014 - Women and Infants’ Hospital of Rhode Island Providence, RI John Wei, M.D., M.S. … Women and Infants’ Hospital of Rhode Island Providence, RI John Wei, M.D., M.S.
  8. www.uspreventiveservicestaskforce.org/home/getfilebytoken/KFZpoMBYuoo8TRW6nhRev8
    October 23, 2023 - In the trial of cisgender women, no congenital abnormalities were observed in infants of those who became … for PrEP during pregnancy is very sparse, al- though 1 trial7 reported no congenital abnormalities in infants
  9. effectivehealthcare.ahrq.gov/sites/default/files/pdf/ace-inhibitor-arb-future_research.pdf
    March 01, 2012 - inhibitors"[tw] OR "DRI"[tw] OR "DRIs"[tw] 53191 #4 AND (English[lang] AND systematic[sb] NOT ("infant … "[MeSH Terms] OR ("infant"[MeSH Terms] OR "child"[MeSH Terms] OR "adolescent"[MeSH Terms] OR ("animals
  10. effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/ace-inhibitor-arb-future_research.pdf
    March 01, 2012 - inhibitors"[tw] OR "DRI"[tw] OR "DRIs"[tw] 53191 #4 AND (English[lang] AND systematic[sb] NOT ("infant … "[MeSH Terms] OR ("infant"[MeSH Terms] OR "child"[MeSH Terms] OR "adolescent"[MeSH Terms] OR ("animals
  11. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/mhs-IV-high-risk-drugs-rapid-response.pdf
    January 01, 2024 - [ti] OR babies[ti] OR baby[ti] OR boy[ti] OR boys[ti] OR child*[ti] OR girl*[ti] OR infancy[ti] OR infant … [ti] OR babies[ti] OR baby[ti] OR boy[ti] OR boys[ti] OR child*[ti] OR girl*[ti] OR infancy[ti] OR infant
  12. www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-248-fullreport.pdf
    December 01, 2019 - Population – infants (29 days to 1 year) (specify age range): No. q.
  13. www.innovations.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-166-fullreport.pdf
    March 01, 2018 - Population – infants (29 days to 1 year) (specify age range): Yes; 90-364 days. q.
  14. www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-166-fullreport.pdf
    March 01, 2018 - Population – infants (29 days to 1 year) (specify age range): Yes; 90-364 days. q.
  15. www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-166-fullreport.pdf
    March 01, 2018 - Population – infants (29 days to 1 year) (specify age range): Yes; 90-364 days. q.
  16. www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-247-fullreport.pdf
    December 01, 2019 - Population – infants (29 days to 1 year) (specify age range): No. q.
  17. www.innovations.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-247-fullreport.pdf
    December 01, 2019 - Population – infants (29 days to 1 year) (specify age range): No. q.
  18. www.cahps.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-247-fullreport.pdf
    December 01, 2019 - Population – infants (29 days to 1 year) (specify age range): No. q.
  19. www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-247-fullreport.pdf
    December 01, 2019 - Population – infants (29 days to 1 year) (specify age range): No. q.
  20. www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-166-fullreport.pdf
    March 01, 2018 - Population – infants (29 days to 1 year) (specify age range): Yes; 90-364 days. q.